Live Breaking News & Updates on Consumer Healthcare Company Limited

Stay updated with breaking news from Consumer healthcare company limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Redirecting to Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

Takeda Completes Sale of Select Non-Core Assets to Cheplapharm
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda’s Europe and Canada Business Unit. This divestment agreement was first announced in September 2020.
The divested portfolio is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories that includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. In line with Takeda’s long-term growth strategy, these products, while addressing key patient needs in these countries, are outside of Takeda’s five core business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and N ....

United States , Takeda Europe , Exchange Commission , Takeda Pharmaceutical Company Limited , Blackstone Group Inc , Asia Pacific To Celltrion Inc , Takeda Pharmaceutical Company , Canada Business , Rare Diseases , Plasma Derived Therapies , Fiscal Years , Consumer Healthcare Company Limited , Oscara Co , Blackstone Group , Emerging Markets Business Unit , Tachosil Fibrin Sealant Patch , Corza Health , Pharmaceutical Company Limited , Rare Genetic , Annual Report , Hasten Biopharmaceutic , Latin America , Near East , Middle East , Asia Pacific , ஒன்றுபட்டது மாநிலங்களில் ,

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD - Press Release

Dec 21, 2020 07:00 UTC
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
OSAKA, Japan (Business Wire) Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)
1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil ....

United States , Kazumi Kobayashi , Ricardo Marek , Justine Grosvenor , Christopher Oreilly , Ray Capital Management Limited , Takeda Pharmaceutical Company Limited , China To Hasten Biopharmaceutic Co Ltd , Takeda Pharmaceutical Company , Exchange Commission , Asia Pacific To Celltrion Inc , Blackstone Group Inc , White Case , Business Wire , Feidong County , Hefei City , Rare Diseases , Plasma Derived Therapies , Emerging Markets Business Unit , Gray Capital , Costa Saroukos , Chief Financial Officer , Consumer Healthcare Company Limited , Oscara Co , Blackstone Group , Tachosil Fibrin Sealant Patch ,

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.

United States , Ricardo Marek , Ray Capital Management Limited , Takeda Pharmaceutical Company Limited , China To Hasten Biopharmaceutic Co Ltd , Takeda Pharmaceutical Company , Exchange Commission , Blackstone Group Inc , White Case , Feidong County , Hefei City , Rare Diseases , Plasma Derived Therapies , Emerging Markets Business Unit , Gray Capital , Costa Saroukos , Chief Financial Officer , Consumer Healthcare Company Limited , Oscara Co , Blackstone Group , Tachosil Fibrin Sealant Patch , Corza Health , Bofa Securities , Pharmaceutical Company Limited , Rare Genetic , Annual Report ,

Redirecting to Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

December 21, 2020 healthcare
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil®. While the products included in the sale continue to ....

United States , Ricardo Marek , Ray Capital Management Limited , Takeda Pharmaceutical Company Limited , China To Hasten Biopharmaceutic Co Ltd , Takeda Pharmaceutical Company , Exchange Commission , Asia Pacific To Celltrion Inc , Blackstone Group Inc , White Case , Feidong County , Hefei City , Rare Diseases , Plasma Derived Therapies , Emerging Markets Business Unit , Gray Capital , Costa Saroukos , Chief Financial Officer , Consumer Healthcare Company Limited , Oscara Co , Blackstone Group , Tachosil Fibrin Sealant Patch , Corza Health , Bofa Securities , Pharmaceutical Company Limited , Rare Genetic ,